ROSE-AHF and lessons learned

Amit K. Jain; Horng H. Chen

doi:10.1007/s11897-014-0208-6

ROSE-AHF and lessons learned

Amit K. Jain, Horng H. Chen

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Nesiritide and dopamine have been recognized for some time as potential renal adjunct therapies in the management of patients with acute heart failure (AHF). Several studies have yielded conflicting evidence of the efficacy of both medications in enhancing the renal function of patients with AHF. The Renal Optimization Strategies Evaluation (ROSE) study was a multicenter double-blind placebo controlled trial designed to assess the potential renoprotective effects of low-dose nesiritide and dopamine in AHF patients with renal dysfunction. This article will focus on previous research, summary of results, and lessons learned from the ROSE-AHF trial as well as future directions for clinical research and applications.

Original language	English (US)
Pages (from-to)	260-265
Number of pages	6
Journal	Current heart failure reports
Volume	11
Issue number	3
DOIs	https://doi.org/10.1007/s11897-014-0208-6
State	Published - Sep 2014

Keywords

Acute heart failure
Dopamine
Heart failure therapy
Natriuretic peptides
Nesiritide
ROSE-AHF
Renal dysfunction

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-014-0208-6

Cite this

@article{191e8eb68f3041f88f3ee6bc3c78a604,

title = "ROSE-AHF and lessons learned",

abstract = "Nesiritide and dopamine have been recognized for some time as potential renal adjunct therapies in the management of patients with acute heart failure (AHF). Several studies have yielded conflicting evidence of the efficacy of both medications in enhancing the renal function of patients with AHF. The Renal Optimization Strategies Evaluation (ROSE) study was a multicenter double-blind placebo controlled trial designed to assess the potential renoprotective effects of low-dose nesiritide and dopamine in AHF patients with renal dysfunction. This article will focus on previous research, summary of results, and lessons learned from the ROSE-AHF trial as well as future directions for clinical research and applications.",

keywords = "Acute heart failure, Dopamine, Heart failure therapy, Natriuretic peptides, Nesiritide, ROSE-AHF, Renal dysfunction",

author = "Jain, {Amit K.} and Chen, {Horng H.}",

note = "Funding Information: Horng H. Chen has received financial support through grants from the National Institutes of Health (NIH) and Scios, Inc.; has received royalties from Nile Therapeutics, Anexon, and UpToDate; holds the patent issued for chimeric natriuretic peptides; and is the co-founder of Zumbro Discovery.",

year = "2014",

month = sep,

doi = "10.1007/s11897-014-0208-6",

language = "English (US)",

volume = "11",

pages = "260--265",

journal = "Current heart failure reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - ROSE-AHF and lessons learned

AU - Jain, Amit K.

AU - Chen, Horng H.

N1 - Funding Information: Horng H. Chen has received financial support through grants from the National Institutes of Health (NIH) and Scios, Inc.; has received royalties from Nile Therapeutics, Anexon, and UpToDate; holds the patent issued for chimeric natriuretic peptides; and is the co-founder of Zumbro Discovery.

PY - 2014/9

Y1 - 2014/9

N2 - Nesiritide and dopamine have been recognized for some time as potential renal adjunct therapies in the management of patients with acute heart failure (AHF). Several studies have yielded conflicting evidence of the efficacy of both medications in enhancing the renal function of patients with AHF. The Renal Optimization Strategies Evaluation (ROSE) study was a multicenter double-blind placebo controlled trial designed to assess the potential renoprotective effects of low-dose nesiritide and dopamine in AHF patients with renal dysfunction. This article will focus on previous research, summary of results, and lessons learned from the ROSE-AHF trial as well as future directions for clinical research and applications.

AB - Nesiritide and dopamine have been recognized for some time as potential renal adjunct therapies in the management of patients with acute heart failure (AHF). Several studies have yielded conflicting evidence of the efficacy of both medications in enhancing the renal function of patients with AHF. The Renal Optimization Strategies Evaluation (ROSE) study was a multicenter double-blind placebo controlled trial designed to assess the potential renoprotective effects of low-dose nesiritide and dopamine in AHF patients with renal dysfunction. This article will focus on previous research, summary of results, and lessons learned from the ROSE-AHF trial as well as future directions for clinical research and applications.

KW - Acute heart failure

KW - Dopamine

KW - Heart failure therapy

KW - Natriuretic peptides

KW - Nesiritide

KW - ROSE-AHF

KW - Renal dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84906066903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906066903&partnerID=8YFLogxK

U2 - 10.1007/s11897-014-0208-6

DO - 10.1007/s11897-014-0208-6

M3 - Article

C2 - 24966060

AN - SCOPUS:84906066903

SN - 1546-9530

VL - 11

SP - 260

EP - 265

JO - Current heart failure reports

JF - Current heart failure reports

IS - 3

ER -

ROSE-AHF and lessons learned

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this